Sirona Biochem Corp. (SRBCF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.54 Million CAD | 28.52% |
| 2022 | -3.55 Million CAD | -54.26% |
| 2021 | -2.3 Million CAD | 44.21% |
| 2020 | -4.13 Million CAD | 9.14% |
| 2019 | -4.54 Million CAD | -257.32% |
| 2018 | -1.27 Million CAD | 71.45% |
| 2017 | -4.46 Million CAD | -49.94% |
| 2016 | -2.97 Million CAD | 16.11% |
| 2015 | -3.54 Million CAD | -0.58% |
| 2014 | -3.52 Million CAD | -26.61% |
| 2013 | -2.78 Million CAD | 6.66% |
| 2012 | -2.98 Million CAD | -19.06% |
| 2011 | -2.5 Million CAD | -134.25% |
| 2010 | -1.06 Million CAD | 12.02% |
| 2009 | -1.21 Million CAD | -1152.31% |
| 2008 | -97.08 Thousand CAD | 55.49% |
| 2007 | -218.12 Thousand CAD | -3635316.67% |
| 2006 | -6.00 CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -417.95 Thousand CAD | 42.9% |
| 2024 Q1 | -731.91 Thousand CAD | -15.94% |
| 2024 Q3 | -885.17 Thousand CAD | -111.79% |
| 2023 Q2 | -763.91 Thousand CAD | -22.75% |
| 2023 FY | -2.54 Million CAD | 28.52% |
| 2023 Q1 | -622.32 Thousand CAD | -71.02% |
| 2023 Q4 | -631.28 Thousand CAD | -20.09% |
| 2023 Q3 | -525.66 Thousand CAD | 31.19% |
| 2022 Q4 | -363.88 Thousand CAD | 4.52% |
| 2022 Q3 | -381.1 Thousand CAD | 49.95% |
| 2022 FY | -3.55 Million CAD | -54.26% |
| 2022 Q1 | -2.05 Million CAD | -583.0% |
| 2022 Q2 | -761.44 Thousand CAD | 62.88% |
| 2021 Q1 | -675.59 Thousand CAD | -65.95% |
| 2021 FY | -2.3 Million CAD | 44.21% |
| 2021 Q2 | -836.59 Thousand CAD | -23.83% |
| 2021 Q4 | -300.34 Thousand CAD | 77.42% |
| 2021 Q3 | -1.33 Million CAD | -59.02% |
| 2020 Q3 | -1.2 Million CAD | -97.15% |
| 2020 Q4 | -407.12 Thousand CAD | 66.27% |
| 2020 Q2 | -612.18 Thousand CAD | 67.91% |
| 2020 Q1 | -1.9 Million CAD | -46.41% |
| 2020 FY | -4.13 Million CAD | 9.14% |
| 2019 Q2 | -1.29 Million CAD | -122.24% |
| 2019 Q3 | -1.37 Million CAD | -6.23% |
| 2019 FY | -4.54 Million CAD | -257.32% |
| 2019 Q4 | -1.3 Million CAD | 5.1% |
| 2019 Q1 | -581.5 Thousand CAD | 9.99% |
| 2018 FY | -1.27 Million CAD | 71.45% |
| 2018 Q4 | -646.06 Thousand CAD | -713.59% |
| 2018 Q1 | -117.85 Thousand CAD | 95.41% |
| 2018 Q2 | -614.61 Thousand CAD | -421.48% |
| 2018 Q3 | 105.29 Thousand CAD | 117.13% |
| 2017 FY | -4.46 Million CAD | -49.94% |
| 2017 Q3 | -624.58 Thousand CAD | 10.94% |
| 2017 Q2 | -701.31 Thousand CAD | -24.13% |
| 2017 Q1 | -565 Thousand CAD | 36.76% |
| 2017 Q4 | -2.56 Million CAD | -311.39% |
| 2016 Q2 | -378.02 Thousand CAD | 51.8% |
| 2016 Q4 | -893.47 Thousand CAD | 2.78% |
| 2016 Q3 | -918.98 Thousand CAD | -143.1% |
| 2016 FY | -2.97 Million CAD | 16.11% |
| 2016 Q1 | -784.27 Thousand CAD | -30.61% |
| 2015 FY | -3.54 Million CAD | -0.58% |
| 2015 Q1 | -930.66 Thousand CAD | -83.67% |
| 2015 Q4 | -600.46 Thousand CAD | 45.5% |
| 2015 Q3 | -1.1 Million CAD | -20.63% |
| 2015 Q2 | -913.28 Thousand CAD | 1.87% |
| 2014 FY | -3.52 Million CAD | -26.61% |
| 2014 Q4 | -506.71 Thousand CAD | 26.21% |
| 2014 Q3 | -686.72 Thousand CAD | 48.07% |
| 2014 Q2 | -1.32 Million CAD | -30.96% |
| 2014 Q1 | -1 Million CAD | -38.74% |
| 2013 Q4 | -727.84 Thousand CAD | -14.52% |
| 2013 FY | -2.78 Million CAD | 6.66% |
| 2013 Q2 | -706.46 Thousand CAD | 1.16% |
| 2013 Q1 | -714.75 Thousand CAD | 45.34% |
| 2013 Q3 | -635.53 Thousand CAD | 10.04% |
| 2012 Q3 | -372.08 Thousand CAD | 51.68% |
| 2012 Q2 | -770.03 Thousand CAD | -44.3% |
| 2012 FY | -2.98 Million CAD | -19.06% |
| 2012 Q1 | -533.62 Thousand CAD | 50.23% |
| 2012 Q4 | -1.3 Million CAD | -251.41% |
| 2011 Q2 | -504.74 Thousand CAD | -9.52% |
| 2011 Q3 | -487.5 Thousand CAD | 3.42% |
| 2011 Q1 | -460.86 Thousand CAD | 3.43% |
| 2011 FY | -2.5 Million CAD | -134.25% |
| 2011 Q4 | -1.07 Million CAD | -119.92% |
| 2010 Q1 | -202.62 Thousand CAD | 28.24% |
| 2010 Q4 | -477.22 Thousand CAD | -127.36% |
| 2010 Q2 | -179.52 Thousand CAD | 11.4% |
| 2010 Q3 | -209.9 Thousand CAD | -16.92% |
| 2010 FY | -1.06 Million CAD | 12.02% |
| 2009 Q2 | -663.76 Thousand CAD | -840.74% |
| 2009 Q3 | -199.08 Thousand CAD | 70.01% |
| 2009 FY | -1.21 Million CAD | -1152.31% |
| 2009 Q4 | -282.36 Thousand CAD | -41.83% |
| 2009 Q1 | -70.55 Thousand CAD | -146.69% |
| 2008 Q4 | -28.6 Thousand CAD | -94.32% |
| 2008 Q3 | -14.71 Thousand CAD | 61.91% |
| 2008 FY | -97.08 Thousand CAD | 55.49% |
| 2008 Q1 | -15.12 Thousand CAD | 27.62% |
| 2008 Q2 | -38.64 Thousand CAD | -155.56% |
| 2007 FY | -218.12 Thousand CAD | -3635316.67% |
| 2007 Q3 | -18.08 Thousand CAD | 47.81% |
| 2007 Q1 | -144.48 Thousand CAD | 0.0% |
| 2007 Q4 | -20.88 Thousand CAD | -15.49% |
| 2007 Q2 | -34.65 Thousand CAD | 76.01% |
| 2006 FY | -6.00 CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 96.607% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 61.327% |
| SQZ Biotechnologies Company | -79.46 Million USD | 96.8% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 104.8% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 103.905% |
| Mesoblast Limited | -87.95 Million USD | 97.109% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -39.695% |
| Genus plc | 7.9 Million USD | 132.192% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 76.65% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 31.455% |
| Marizyme, Inc. | -65.34 Million USD | 96.108% |
| ContraFect Corporation | -65.15 Million USD | 96.097% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 71.244% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 47.95% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -47.222% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 12.073% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 68.446% |
| MultiCell Technologies, Inc. | -380.07 USD | -669037.264% |
| Accustem Sciences Inc. | -3.74 Million USD | 32.117% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 95.08% |
| EV Biologics, Inc. | -1.26 Million USD | -100.704% |
| Q BioMed Inc. | -2.05 Million USD | -23.932% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 31.873% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -302.145% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -6.818% |
| Biomind Labs Inc. | -1.21 Million USD | -109.433% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 75.889% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 67.82% |
| Skye Bioscience, Inc. | -37.64 Million USD | 93.244% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -17.208% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -16881.771% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 63.579% |
| IMV Inc. | -36.48 Million USD | 93.03% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 83.976% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 56.282% |
| GB Sciences, Inc. | -1.36 Million USD | -86.769% |
| Alpha Cognition Inc. | -13.77 Million USD | 81.534% |
| HST Global, Inc. | -146.21 Thousand USD | -1639.409% |
| CSL Limited | 2.64 Billion USD | 100.096% |
| Halberd Corporation | -79.67 Thousand USD | -3091.915% |
| Enzolytics Inc. | -2.17 Million USD | -16.83% |
| Resverlogix Corp. | -3.61 Million USD | 29.552% |
| Affymax, Inc. | -14.42 Million USD | 82.368% |
| SYBLEU INC | -180.3 Thousand USD | -1310.501% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 19.81% |
| argenx SE | -295.05 Million USD | 99.138% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 95.937% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 2695.092% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 35.988% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 15.959% |
| AVAX Technologies, Inc. | -6.41 Million USD | 60.347% |
| Zenith Capital Corp. | -10.59 Million USD | 75.999% |
| Genscript Biotech Corporation | -95.47 Million USD | 97.336% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -10842.217% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 38.658% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -4107.75% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 95.742% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 18.008% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -140.819% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -30.47% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 33.407% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -26.835% |
| BioStem Technologies, Inc. | -8.48 Million USD | 70.02% |
| ONE Bio Corp. | 8.67 Million USD | 129.311% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -476.205% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -90.44% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -44.93% |
| Agentix Corp. | -1.37 Million USD | -85.065% |
| LadRx Corporation | 400.44 Thousand USD | 735.094% |
| Cell Source, Inc. | -5.32 Million USD | 52.207% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -512.11% |
| Regen BioPharma, Inc. | 1.02 Million USD | 348.478% |
| Regen BioPharma, Inc. | 1.02 Million USD | 348.478% |
| NovAccess Global Inc. | -4.76 Million USD | 46.675% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 136.727% |
| Itoco Inc. | -1.86 Million USD | -36.073% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 42.754% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -52.378% |
| Kadimastem Ltd | -3.3 Million USD | 23.106% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -830.202% |
| CytoDyn Inc. | -49.84 Million USD | 94.897% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -3117.884% |
| Mobile Lads Corp. | -2.26 Million USD | -12.367% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1014.813% |
| Qrons Inc. | -789.34 Thousand USD | -222.189% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -170.113% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -21.819% |
| Rebus Holdings, Inc. | -1.02 Million USD | -149.332% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -57.694% |
| International Stem Cell Corporation | -131 Thousand USD | -1841.366% |
| Bioxytran, Inc. | -4.28 Million USD | 40.58% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -4586.008% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -0.512% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 94.71% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -20.302% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -225.68% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 19.723% |
| Neutra Corp. | -233.46 Thousand USD | -989.324% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 87.466% |
| PureTech Health plc | -65.69 Million USD | 96.129% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 88.041% |
| IXICO plc | -1.17 Million USD | -115.89% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 74.381% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 95.548% |
| CSL Limited | 2.64 Billion USD | 100.096% |
| Cellectis S.A. | -103.17 Million USD | 97.535% |